Status:
COMPLETED
LAPAS Study: Insulin Glargine in Type 2 Diabetes Mellitus
Lead Sponsor:
Sanofi
Conditions:
Diabetes Mellitus, Type 2
Eligibility:
All Genders
18+ years
Brief Summary
The objective of this protocol is to confirm the efficacy and safety profile of Lantus in every day medical practice, in type 2 diabetic patients, have been treated with any other insulin but who did ...
Eligibility Criteria
Inclusion
- Patients with type 2 diabetes mellitus,
- Having been treated with any other insulin, but who did not reach the target of A1c=7%.
- Ability and willingness to perform Self Monitoring Blood Glucose measurement
Exclusion
- Will follow the prescribing information (Summary of Product Characteristics).
- The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Key Trial Info
Start Date :
March 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2008
Estimated Enrollment :
1007 Patients enrolled
Trial Details
Trial ID
NCT00423215
Start Date
March 1 2006
End Date
May 1 2008
Last Update
June 15 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sanofi-Aventis Administrative Office
Netanya, Israel